Volume 1, Issue 2 (November 2022)
Health Science Monitor 2022, 1(2): 125-130 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shirani F, Javadzadeh A, rahaeebakhshizadiabdo A. Epidemiology and clinical outcome and its main determinants among patients with inflammatory myositis. Health Science Monitor 2022; 1 (2) :125-130
URL: http://hsm.umsu.ac.ir/article-1-70-en.html
URL: http://hsm.umsu.ac.ir/article-1-70-en.html
Department of Internal Medicine, School of Medicine, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran
Abstract: (518 Views)
Background & Aims: Despite the proper understanding of pathophysiological aspects and recent development in therapeutic approaches, the outcome of patients suffering from inflammatory myositis remains unsatisfactory. In addition, there is no clinical information and a clear outlook for this disease in the community. This study aimed to evaluate the outcome of patients with inflammatory myositis (response rate to treatment) and to determine the related and predictive factors of this outcome in these patients.
Materials & Methods: This historical cohort study was performed on 80 patients suffering from inflammatory myositis. By retrospectively reviewing the patient records in the hospital, basic information was extracted and through telephone calls, the outcome status of the disease, and response to treatment were assessed during follow-up and categorized as complete remission, partial remission, and no remission.
Results: Within the follow-up time, 40.0% were completely treated (complete remission), 3.8% had no proper response to treatment (incomplete remission), and 13.8% did not respond to the treatment. Also, 23.8% did not refer for further treatment at least six months from the start of treatment. No death was reported within the follow-up time. We found an association between the quality of treatment response and baseline parameters, including the rate of receiving intravenous immune globulin regimen, time of symptoms onset, gender, different patterns of disease, and disease subtype.
Conclusion: A notable number of inflammatory myositis patients still do not respond to routine treatment, and we, in fact, are at the forefront of managing the disease.
Materials & Methods: This historical cohort study was performed on 80 patients suffering from inflammatory myositis. By retrospectively reviewing the patient records in the hospital, basic information was extracted and through telephone calls, the outcome status of the disease, and response to treatment were assessed during follow-up and categorized as complete remission, partial remission, and no remission.
Results: Within the follow-up time, 40.0% were completely treated (complete remission), 3.8% had no proper response to treatment (incomplete remission), and 13.8% did not respond to the treatment. Also, 23.8% did not refer for further treatment at least six months from the start of treatment. No death was reported within the follow-up time. We found an association between the quality of treatment response and baseline parameters, including the rate of receiving intravenous immune globulin regimen, time of symptoms onset, gender, different patterns of disease, and disease subtype.
Conclusion: A notable number of inflammatory myositis patients still do not respond to routine treatment, and we, in fact, are at the forefront of managing the disease.
Type of Study: Research |
Subject:
Special
Received: 2022/09/8 | Accepted: 2022/10/17 | Published: 2022/11/19
Received: 2022/09/8 | Accepted: 2022/10/17 | Published: 2022/11/19
References
1. Tieu J, Lundberg IE, Limaye V. Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol. 2016 Feb;30(1):149-68. [DOI] [PMID]
2. Gupta L, Naveen R, Gaur P, Agarwal V, Aggarwal R. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. Semin Arthritis Rheum. 2021 Feb;51(1):113-120. [DOI] [PMID]
3. Aldrich J, Pundole X, Tummala S, Palaskas N, Andersen CR, Shoukier M, et al. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. Arthritis Rheumatol. 2021 May;73(5):866-874. [DOI] [PMID]
4. Ceribelli A, De Santis M, Isailovic N, Gershwin ME, Selmi C. The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review. Clin Rev Allergy Immunol. 2017 Feb;52(1):58-70. [DOI] [PMID]
5. Lim LSH, Feldman BM. Using Registry Data to Understand Disease Evolution in Inflammatory Myositis and Other Rheumatic Diseases. Curr Rheumatol Rep. 2019 Dec 12;22(1):2. [DOI] [PMID]
6. Khadilkar SV, Dhamne MC. What is New in Idiopathic Inflammatory Myopathies: Mechanisms and Therapies. Ann Indian Acad Neurol. 2020 Jul-Aug;23(4):458-467. [DOI] [PMID]
7. Dayal NA, Isenberg DA. Assessment of inflammatory myositis. Curr Opin Rheumatol. 2001 Nov;13(6):488-92. [DOI] [PMID]
8. García-De La Torre I. Clinical Usefulness of Autoantibodies in Idiopathic Inflammatory Myositis. Front Immunol. 2015 Jun 25;6:331. [DOI]
9. Nuño L, Joven B, Carreira P, Maldonado V, Larena C, Llorente I, et al. Multicenter registry on inflammatory myositis from the Rheumatology Society in Madrid, Spain: Descriptive Analysis. Reumatol Clin. 2017 Nov-Dec;13(6):331-337. [DOI]
10. Işık M, Bilgen Ş, Doğan İ, Kılıç L. Inflammatory myopathies: One-center experience. Eur J Rheumatol. 2014 Sep;1(3):96-100. [DOI] [PMID] [PMCID]
11. Friedmann I. Inflammatory myositis. ORL J Otorhinolaryngol Relat Spec. 2002 Jan-Feb;64(1):57-8. [DOI] [PMID]
12. Wendling D. Biologics in the treatment of primary inflammatory myositis. Joint Bone Spine. 2007 Jul;74(4):316-8. [DOI] [PMID]
13. Nicolò Pipitone 1, Carlo Salvarani 1 2. Treatment of inflammatory myositis. Expert Rev Clin Immunol. 2018 Jul;14(7):607-621. [DOI] [PMID]
14. de Salles Painelli V, Gualano B, Artioli GG, de Sá Pinto AL, Bonfá E, Lancha Junior AH, et al .The possible role of physical exercise on the treatment of idiopathic inflammatory myositis. Autoimmun Rev. 2009 Mar;8(5):355-9. Choy E H S, Isenberg D A. Treatment of dermatomyositis and polymyositis. Rheumatology 2002417-13. [DOI] [PMID]
15. Dalakas M. Polymyositis and dermatomyositis. Lancet 2003362971-982. [DOI]
16. Oddis C. Idiopathic inflammatory myositis: a treatment update. Curr Rheumatol Rep 20035431-436. [DOI]
17. Mastaglia F, Garlepp M, Phillips B.et al Inflammatory myositis: clinical, diagnostic and therapeutic aspects. Muscle Nerve 200327407-425. [DOI]
18. Amato A A, Grigs R C. Treatment of idiopathic inflammatory myositis. Curr Opin Neurol 200316569-575. [DOI]
19. Kiely P, Heron C, Bruckner F. Presentation and management of idiopathic inflammatory muscle disease: four case reports and commentary from a series of 78 patients. Rheumatology 200342575-582. [DOI]
20. van de Vlekkert J, Hoogendijk JE, de Visser M. Long-term follow-up of 62 patients with myositis. Journal of neurology 2014; 261: 992-998. [DOI] [PMID]
21. Amaral Silva M, Cogollo E, Isenberg DA. Why do patients with myositis die? A retrospective analysis of a single-centre cohort. Clinical and experimental rheumatology 2016; 34: 820-826. [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
